WO2005027968A1 - ダウン症候群治療剤 - Google Patents
ダウン症候群治療剤 Download PDFInfo
- Publication number
- WO2005027968A1 WO2005027968A1 PCT/JP2004/013636 JP2004013636W WO2005027968A1 WO 2005027968 A1 WO2005027968 A1 WO 2005027968A1 JP 2004013636 W JP2004013636 W JP 2004013636W WO 2005027968 A1 WO2005027968 A1 WO 2005027968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- down syndrome
- agent
- syndrome
- improving
- donezil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel pharmaceutical use of donebezil, an acetylcholinesterase inhibitor, or a pharmacologically acceptable salt thereof in Down's syndrome. More particularly, the present invention relates to a method for treating Down's syndrome with donezil hydrochloride, and a pharmaceutical composition containing donezil hydrochloride for treating Down's syndrome.
- Down syndrome is the most frequent chromosomal abnormality, and is caused mainly by trisomy 21 with chromosome 21 excess (standard trisomy 90% or more).
- the birth frequency of Down syndrome patients is almost one in 1,000, and is characterized by delayed psychomotor development after birth.
- Down syndrome is associated with various complications, congenital heart disease, gastrointestinal malformation, epilepsy, pneumonia and other infectious diseases in infants, including neonates, and obesity in childhood to school. It is easy to cause diseases such as acute paraplegia, alopecia areata, thyroid disease, refraction abnormality of acute leukemia eye, and otitis media with effusion (for example, see Non-Patent Document 1).
- Alzheimer's disease In adults, the neuropathological symptoms of Alzheimer's disease are known to increase with age. For example, it has been confirmed that, in their 30s, an increase in amyloid deposition senile plaques and changes in neurofibrils from their 40s have been confirmed. Furthermore, in the late 30's or over 40's, neuropathological symptoms progress, and the onset of Aldino Ima dementia or behavioral changes due to dementia are observed. It is reported that 75% of patients with Down syndrome who are over 60 years of age have symptoms of Aln's disease (see, for example, Non-Patent Documents 1 and 2).
- Down's syndrome provides medical treatment and early childhood, and comprehensive medical treatment such as childcare, education, and training through early detection and early diagnosis, which cannot be treated fundamentally.
- Medical management treatment techniques for infectious diseases, congenital heart disease, and complications such as gastrointestinal malformation are developing.
- the survival rate and average age of death of Down's syndrome patients have increased significantly.
- nursing care appropriate behavior and living skills
- Various nursing programs have been developed with the aim of bringing about good relations with society, such as improvement (for example, see Non-Patent Document 3).
- Non-Patent Document 4 the IQ is playing a major role in learning about language function in childhood, and it has been reported that patients with an IQ of 50 or less do not have a sufficient learning effect.
- Non-Patent Document 3 In a double-blind study of 25 human children with Down syndrome, aggression, agitation, sexual arousal, light sleep, decreased appetite, and other effects on the central nervous system were observed. However, the improvement effect on the cognitive function was not obtained (for example, see Non-Patent Document 3).
- donedil hydrochloride is an agent having an acetylcholinesterase inhibitory action (for example, see Patent Document 1). Therefore, currently, donezil hydrochloride is used as a drug to suppress the progression of dementia symptoms in mild and moderate Alzheimer's dementia, and 3 mg once daily for the purpose of suppressing the occurrence of gastrointestinal side effects in adults. One to two weeks after the start of administration, 5 mg (useful amount) is administered once a day.
- Patent Document 1 Japanese Patent No. 2578475
- Non-patent document 1 Valentine Dmitriev, edited by Kazuko Takei, et al., ⁇ Development of Down Syndrome and Nursing Care--Improving Understanding '', First Edition, Kyodo Medical Publishing, June 20, 1992, p. .1-12, P.49-53, p.62-69
- Non-Patent Document 2 Shuichi Ikeda and 5 others, ⁇ Relationship between Alzheimer's dementia and Downstream Syndrome and Apolipoprotein E phenotype '', Amyloidosis Research Group, 1995, 1996, p. 86-89
- Non-Patent Document 3 Nancy J Roizen and 1 other, ⁇ Down, s syndrome j, The Lancet, 2003, Vol. 361, p.1281-1289
- Non-Patent Document 4 James H. Heller, et al., ⁇ Donepezii for the treatment of language dencits in adults with down syndrome: A preliminary 24-week open trialj, American Journal of Medical Genetics, 2003, Vol. 116, No. 2 No., p.111-116
- Non-Patent Document 5 Timothy H. Moran and 5 others, ⁇ The effect of piracetam on cognitive performance in a mouse model of down's syndromej, Physiology & Behavior, 2002, Vol. 77, p.403-409
- Non-Patent Document 6 James B ⁇ everenz, 1 other, "Early amyloid deposition in the medical temporal lobe of young down syndrome patients: A regional quantitative analysis", Experimental Neurology Vol. 150 p.296- 304
- Non-Patent Document 7 Priya S Kishnani and 5 others, ⁇ Cholinergic the therapy for Down's syndrome '', The Lancet, 1999, Vol. 353, p. 1064
- the sudden regression refers to a sudden regression of living ability and adaptive behavior, and most of the symptoms develop from adolescence to adulthood, for example, around the age of 20, and in early patients by the early 10 years.
- Specific symptoms include sudden and slow movements in daily life, poor expression, decreased conversation, leaning forward posture, and short walking in the movement and behavioral aspects.
- Loss, persistence, etc. interpersonal hypertension and interpersonal impairment were observed, and physical problems include sleep disorders, anorexia, weight loss, incontinence, etc.
- the present inventor has conducted intensive studies on the above-mentioned problems, and as a result, it was found that donezil hydrochloride, a drug for the treatment of dementia of the allergic type I, is effective in treating Down's syndrome, a congenital disease. It was found to be effective as an agent. In other words, it was found that in patients with Down syndrome, mental developmental delay can be improved or mental development can be promoted, and QOL in daily life, such as activities of daily living, independence, sociality, and communication, can be improved.
- QOL in daily life, such as activities of daily living, independence, sociality, and communication, can be improved.
- patients with Down syndrome who are 36 years of age or younger, they can improve mental retardation or promote mental development, and also have Down Syndrome patients with IQ50 or less that are not expected to have a nursing effect on mental retardation. The effect could be found.
- the present invention provides:
- a therapeutic agent for Down syndrome comprising an acetylcholinesterase inhibitor
- an agent for alleviating or improving sudden regression symptoms in Down's syndrome which contains an acetylcholinesterase inhibitor
- a method for treating Down syndrome comprising a step of administering an acetylcholinesterase inhibitor to a patient with Down syndrome;
- a method of improving mental retardation or improving daily life in Down syndrome comprising administering an acetylcholinesterase inhibitor to a patient with Down syndrome;
- a composition for a daily life improving agent in Down syndrome comprising donezil or a pharmacologically acceptable salt thereof,
- composition for an agent for improving mental retardation in Down syndrome which comprises donezil or a pharmaceutically acceptable salt thereof,
- composition for alleviating or improving sudden regression symptoms in Down's syndrome comprising donezil or a pharmacologically acceptable salt thereof,
- a therapeutic agent and a therapeutic method can be provided to a patient with Down syndrome who is a congenital genetic disease and has no fundamental treatment. Improve quality of life in daily life, which is of paramount importance to Down's syndrome patients and their families, e.g., improve daily life with maintaining or improving the patient's mental stability, daily life movements, communication, sociality, etc. And improvement can be realized. Furthermore, the present invention can improve mental retardation or promote mental development, which is one of the characteristics of Down syndrome. Therefore, the present invention can reduce the burden on the family during the child-rearing period until reaching an adult who not only has an effect on the mental development and daily life of the patient with Down syndrome.
- patients can live a stable social life from adolescence to adulthood.
- it has an effect on patients with IQ50 or less, which has been expected to have little effect on nursing care. It improves patients' daily life and facilitates participation in social life.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising donezil or a pharmaceutically acceptable salt thereof having an acetylcholinesterase inhibitory activity, or donezil or a pharmaceutically acceptable salt thereof, in a patient with Down syndrome.
- the object of the present invention can be achieved by administering a substance.
- patients with Down's syndrome are objectively diagnosed by chromosome testing and specialists.
- the patient has a congenital psychomotor developmental delay immediately after birth.
- These psychomotor retardations which vary from individual to individual, affect all areas of daily life, including exercise, communication, cognition, social and interpersonal skills, independence and self-management, autonomy, and learning abilities. Therefore, it is important for patients to participate in social life and group life.
- the subject to which donezil or a pharmacologically acceptable salt thereof is administered to Down's syndrome is not limited to the following, but the behavioral symptoms of Alzheimer's disease-type dementia are given. Patients up to their early 30s who do not show, for example, patients under 36 years of age are preferred. Furthermore, it is desirable to administer to patients under the age of 20 who do not show any decrease in mental function due to Alzheimer's disease.
- a patient with Down syndrome can be improved, mental development can be promoted, and daily life can be improved. Improvement of mental retardation or promotion of mental development can be achieved by comprehensively evaluating behavioral changes and IQ changes in patients in daily life. Changes in a patient's behavior in daily life can be evaluated by objective observation or observation records by a family living with the patient, a physician / caregiver, a school educator or a workplace staff in charge of the patient. In addition, the patient's diary and paintings can be used to determine language functions such as sentence construction and expressiveness, interest and awareness of others, emotional changes, and the composition and color of those sentences and pictures. Power Mental status can also be evaluated qualitatively and numerically. IQ can be evaluated by standard measurement methods in medical or educational settings.
- the assessment of improvement in mental retardation and improvement in daily life in Down's syndrome is not limited to these assessment methods.
- the improvement of daily life includes the mental or emotional stability of the patient, activities of daily living such as personal preparation and occupational skills, motivation or learning ability in learning and occupation, and regularity of life rhythm. Communication skills such as showing interest in others, linguistic functions such as understanding language and expressing language, adaptability to group life, and sociality such as autonomy and aggressiveness in group life. To indicate or improve or promote. Improving daily life refers to the mentally unstable state (weakness, lethargy, irregular life, inappropriate behavior, unsafe behavior) associated with the patient's mental or emotional stability. And rarely appear in the marine environment, including the continuation of a stable state.
- improving daily life is a physical condition that may be mentally affected, such as sleep, menstruation or bowel movements, weight changes to proper weight (ie, diet, etc.), or infections. Includes improvement in physical condition such as resistance to Therefore, the daily life improving agent containing donezil hydrochloride according to the present invention is also an improving agent for the above-mentioned specific behavior.
- Donedil or a pharmacologically acceptable salt thereof used in the present invention is produced by a known method such as the method described in Patent Document 1.
- the present invention is not particularly limited to this, and commercially available products can be easily obtained.
- the pharmacologically acceptable salt in the present invention include salts with inorganic acids and salts with organic acids.
- Preferred examples of salts with inorganic acids include, for example, salts with hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- salts with organic acids include, for example, acetic acid, Examples include salts with succinic acid, fumaric acid, maleic acid, tartaric acid, taenoic acid, lactic acid, stearic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, and the like.
- the formula of donezil hydrochloride is shown below. [0020] [Formula 1]
- a pharmaceutical composition containing donezil or a pharmacologically acceptable salt thereof can be formulated by an ordinary method in the technical field of formulation.
- a liquid, semi-solid or solid preparation can be prepared, and the dosage form and production method are not particularly limited.
- a drug containing donezil hydrochloride can be used by formulating an oral preparation such as a fine granule, a tablet, a capsule, a tablet, a quick disintegrating tablet, a liquid, a suspension, and a syrup.
- a parenteral administration agent it is possible to use a dosage form such as an injection, a lyophilized agent, a suppository, a patch, etc.
- An oral administration agent is preferable.
- a tablet or a fine granule (trade name: Alicebut: Eisai Co., Ltd.), which is a therapeutic agent for mild and moderate Alzheimer's dementia, already used in medical practice can be used.
- excipients include, but are not limited to, gelling agents, stabilizers, pH adjusters, preservatives, preservatives, and the like.
- Excipients include lactose, D-mantol, corn starch, crystalline cellulose, light anhydrous silicic acid, anhydrous calcium phosphate, precipitated calcium carbonate, calcium silicate, cocoa butter, liquid paraffin, soybean oil, olive oil, medium chain
- binders such as fatty acid tridalicelide, glycerin, and propylene glycol, such as polyvinylpyrrolidone, dextrin, hydroxypropylmethylcellulose, methylcellulose, polyvinyl alcohol, sodium carboxymethylcellulose, partially starch arsenide, sodium alginate, pullulan, and gum arabic powder.
- Disintegrators such as low-substituted hydroxypropylcellulose, sodium carboxymethyl starch and crospovidone; sucrose fatty acid esters and stears as lubricants Magnesium phosphate, sodium stearyl fumarate, stearic acid, talc, macrogol, etc., as flavoring agents, citrate, malic acid, sodium glutamate, sodium 5'-inosinate, glucose, fructose, sucrose, Erythritol, maltitol, trehalose, sorbitol, xylitol, aspartame, acesulfame potassium, saccharin sodium, dipotassium glycyrrhizin, etc.
- Antioxidants such as sodium ascorbate, L-cysteine, sodium sulfite, natural vitamin E etc.
- Gelling agents such as carrageenan, pectin, sodium alginate, guar gum, locust Sodium polyphosphate, sodium metaphosphate, etc.
- stabilizers such as bean gum, xanthan gum, carboxybutyl polymer, carboxymethyl cellulose, gelatin, etc.
- pH adjusters citrate, sodium citrate, hydrochloric acid, sodium hydroxide, hydrogen phosphate
- a preservative or preservative such as disodium, sorbic acid, benzoate, and benzene can be used, but are not limited thereto.
- the dose of donezil or a pharmacologically acceptable salt thereof is determined according to the degree of symptoms; age, sex, weight, and sensitivity difference of the patient; administration method; , Interval, properties of pharmaceutical preparation, preparation, type; and the type of active ingredient, and are not particularly limited.
- the administration may be continued at a lower dose than the effective dose for 1 to 2 weeks, and then the effective dose may be administered.
- the dose is usually about 0.05 to 100 mg / day, preferably about 0.1 to 100 mg / day, more preferably about 0.5 to 5 mg / day for an adult. Administer in divided doses.
- the effect of the present invention with almost no side effects can be expected by continuously administering 3 mg Zday with donezil hydrochloride.
- 3MgZda y administration does not increase the blood concentration, if the effect does not appear sufficient, for example, it can be expected the effect of the present invention by extending the 5MgZday.
- Test example 1 The results of a double-blind test administered to Down syndrome patients are shown below.
- a 24-week double-blind study was performed on 14 Down syndrome patients without serious complications shown in Table 1.
- Five patients in the active drug treatment group received one tablet containing 3 mg of donezil hydrochloride for 1 week after the start of administration, and one tablet containing 5 mg or 3 mg of donezil hydrochloride once a day thereafter. Taken after breakfast.
- the placebo group one placebo equivalent to a tablet containing 3 mg of donezil hydrochloride for one week after the start of administration, and one placebo equivalent to a tablet containing 5 mg of donezil hydrochloride for one day thereafter I took it once after breakfast.
- Improvements in overall language functions were also observed, such as improvements in linguistic expression, the number of vocabularies, and expressive linguistic functions, including the ability to compose syntax, and receptive linguistic functions, including the ability to understand meaningful words.
- Effective examples showed improvements in language expression functions, such as uttering strong words, and improvements in activities of daily living, such as faster responses to daily life.
- the mentally stable state was maintained during the administration period, and the effect of improving physical condition was confirmed, such as reducing body weight and approaching proper body weight by living a stable daily life.
- Evaluation results at the time of administration of the active drug showed a higher improvement effect even in subjects with V and deviation, as compared with the evaluation results at the time of placebo administration.
- two patients who did not respond to placebo were evaluated as significantly or slightly more effective by administering active drug. Of these subjects, those who showed remarkable results showed positiveness such as expressing their own opinions and improvement in social characteristics such as communication ability, and improvement in linguistic functions such as the number of vocabulary, semantic comprehension and writing ability. The effect was also recognized.
- placebo was administered, the two cases that were slightly effective were both effective. In one of these cases, work evaluations on payroll statements in the workplace improved, for the first time, scores for aggressiveness and collectiveness.
- the improvement effect at the time of active treatment was clearly qualitatively different from the improvement effect at the time of placebo administration. In other words, only improvement of language ability was confirmed at the time of placebo administration.However, administration of the active drug improves conversational ability, independent use of transportation, and improvement of calculation ability. In several events, the improvement effect of active drug administration was confirmed.
- the blood concentration of each subject was measured 4 weeks after the start of the active drug administration.
- the blood concentration of 8 subjects body weight 42 kg-70 kg; average body weight 55.6 kg
- the blood concentration of 3 subjects body weight 54 kg to 75 kg; average body weight 66.3 kg
- the blood concentration of 3 subjects body weight 54 kg to 75 kg; average body weight 66.3 kg
- the blood concentration of 3 subjects body weight 54 kg to 75 kg; average body weight 66.3 kg
- the blood concentration of 3 subjects was 26.3 to 26.6 ngZmL, and the average was 26.4 ngZmL.
- the blood concentration of donezil hydrochloride was 23 ng / mL or less, and the dose of donezil hydrochloride was 3 mg / day, and no adverse effects were observed in most subjects.
- Test Example 2 Administration to patients showing rapid regression
- Target patients Age 12 years 5 months. IQ47. Vocabulary age 4 years 2 months (by picture vocabulary development test). Age of social life 4 years 6 months (by social life ability test). No dementia symptoms (evaluation by dementia scale for Down's syndrome). There is regression (based on a questionnaire survey on regression).
- the administration starting power was also confirmed for the patient for one month. In daily life, it took more than 30 minutes before administration to a detachable garment, but in about 2-3 minutes after power administration. In addition, the movements for movement were slow before administration, and they were unable to act unless accompanied by a companion, but became able to move after administration. After power administration, which had been determined to be a swaying body, it disappeared in daily life except when listening to music. On the communication side, spontaneous conversations began to be seen, such as requesting permission after administration. 2 weeks after the start of administration After 2 weeks, a regular lifestyle, such as an increase in the amount of food and getting up in the morning Is now available. No particularly serious side effects were noted.
- FIG. 1 shows changes in blood concentration with respect to the dose of donezil hydrochloride.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04773271A EP1666066A4 (en) | 2003-09-19 | 2004-09-17 | DRUG AGAINST THE DOWN SYNDROME |
US10/572,090 US20070054940A1 (en) | 2003-09-19 | 2004-09-17 | Remedy for down's syndrome |
JP2005514057A JPWO2005027968A1 (ja) | 2003-09-19 | 2004-09-17 | ダウン症候群治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-327393 | 2003-09-19 | ||
JP2003327393 | 2003-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005027968A1 true WO2005027968A1 (ja) | 2005-03-31 |
Family
ID=34372870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013636 WO2005027968A1 (ja) | 2003-09-19 | 2004-09-17 | ダウン症候群治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070054940A1 (ja) |
EP (1) | EP1666066A4 (ja) |
JP (1) | JPWO2005027968A1 (ja) |
WO (1) | WO2005027968A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040072744A1 (en) * | 2002-09-12 | 2004-04-15 | Lipps Binie V. | Synthetic peptide as treatment for down's syndrome and schizophrenia |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999011635A1 (en) * | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors |
WO2002032412A2 (en) * | 2000-10-17 | 2002-04-25 | Pfizer Products Inc. | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
US20030092700A1 (en) * | 1996-04-19 | 2003-05-15 | Laszlo Czollner | Benzazepine derivatives, medicaments containing the same and their use to prepare medicaments |
WO2003039467A2 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
JP2003525903A (ja) * | 2000-03-03 | 2003-09-02 | エーザイ株式会社 | コリンエステラーゼ阻害剤の新規使用法 |
-
2004
- 2004-09-17 JP JP2005514057A patent/JPWO2005027968A1/ja not_active Abandoned
- 2004-09-17 WO PCT/JP2004/013636 patent/WO2005027968A1/ja active Application Filing
- 2004-09-17 EP EP04773271A patent/EP1666066A4/en not_active Withdrawn
- 2004-09-17 US US10/572,090 patent/US20070054940A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092700A1 (en) * | 1996-04-19 | 2003-05-15 | Laszlo Czollner | Benzazepine derivatives, medicaments containing the same and their use to prepare medicaments |
WO1999011635A1 (en) * | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors |
JP2003525903A (ja) * | 2000-03-03 | 2003-09-02 | エーザイ株式会社 | コリンエステラーゼ阻害剤の新規使用法 |
WO2002032412A2 (en) * | 2000-10-17 | 2002-04-25 | Pfizer Products Inc. | Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
WO2003039467A2 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid. |
Non-Patent Citations (13)
Title |
---|
DATABASE MEDLINE [online] 2002, LOTT I.T. ET AL.: "Down syndrome and Alzheimer disease: response to donepezil", XP002986249, accession no. STN Database accession no. 2002371966 * |
DATABASE MEDLINE [online] 2002, PRASHER V.P. ET AL.: "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - pilot study", XP002986250, accession no. STN Database accession no. 2002196557 * |
DATABASE MEDLINE [online] 2003, HELLER J.H. ET AL.: "Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial", XP002986248, accession no. STN Database accession no. 2002730093 * |
HELLER J.H. ET AL, AMERICAN JOURNAL OF MEDICAL GENETICS, vol. 116A, no. 2, 15 January 2003 (2003-01-15), pages 11 - 116 * |
HEMINGWAY-ELTOMEY J.M. ET AL.: "Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome", AM. J. PSYCHIATRY, vol. 156, no. 9, 1999, pages 1470, XP002986247 * |
KISHNANI PS. ET AL.: "Cholinergic therapy for Down's syndrome", LANCET, vol. 353, no. 9158, 1999, pages 1064 - 1065, XP004266160 * |
KISHNANI PS. ET AL.: "Donepezil for Down's syndrome", AM. J. PSYCHIATRY, vol. 158, no. 1, 2001, pages 143, XP002986246 * |
KONDO T. ET AL.: "Ensan donepezil toyo ni kansuru down shokogun kanja no nichijo seikatsu noryoku kaizen ni kansuru kento", THE JOURNAL OF THE JAPAN PEDIATRIC SOCIETY, vol. 108, no. 2, 1 February 2004 (2004-02-01), pages 178, XP002986244 * |
LOTT I.T. ET AL, ARCHIVES OF NEUROLOGY, vol. 59, no. 7, 2002, pages 1133 - 1136 * |
LOTT IT ET AL.: "Donepezil in down syndrome and Alzheimer disease: a pilot study", RESEARCH AND PRACTICE IN ALZHEIMER'S DISEASE, vol. 7, 2003, pages 204 - 208, XP002986245 * |
NAKAJIMA M. ET AL.: "Ensan donepezil toyo ni yoru down shokogun kanja no nichijo seikatsu noryoku kaizen ni kansuru kenkyu", NIPPON YAKUGAKUKAI NENKAI KOEN YOSHISHU, vol. 124, no. 4, 5 March 2004 (2004-03-05), pages 140, XP002986243 * |
PRASHER V.P. ET AL, INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, vol. 17, no. 03, 2002, pages 270 - 278 * |
See also references of EP1666066A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1666066A1 (en) | 2006-06-07 |
JPWO2005027968A1 (ja) | 2007-11-15 |
EP1666066A4 (en) | 2007-03-28 |
US20070054940A1 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
Catania et al. | Pharmacological and clinical overview of cloperastine in treatment of cough | |
WO2011020061A2 (en) | Compositions and methods of for treating bipolar disorder | |
JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および/または神経精神医学的障害を改善するための4−アミノピリジンの使用 | |
US20240277732A1 (en) | Compositions and methods for treating brain-gut disorders | |
US20230255914A1 (en) | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders | |
US20230372335A1 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
Starkstein et al. | Apathy and depression following stroke | |
JPH0920666A (ja) | 成熟遅延および類似疾患の治療用医薬組成物 | |
CN118555956A (zh) | 用于治疗难治性抑郁症的赛洛西宾和辅助血清素再摄取抑制剂 | |
WO2005027968A1 (ja) | ダウン症候群治療剤 | |
Kemp | Role of leukotriene receptor antagonists in pediatric asthma | |
CA3194825A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
JP2014065695A (ja) | ロイシンを含有する睡眠改善剤 | |
Brasić et al. | Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation | |
TWI681771B (zh) | 苯甲酸鹽用於預防或治療泛自閉症障礙之方法 | |
Richert et al. | A review of common sleep disorders | |
Caldwell et al. | Vitamin deficiency and the psychoses | |
US20240197704A1 (en) | Treatment methods and compositions comprising perampanel | |
JPH10130151A (ja) | 特定の神経運動障害および精神−知力障害の処置に有用な医薬組成物を得るためのスルブチアミンの用途 | |
WO2023186835A1 (en) | Treatment of mental disorders | |
US20200038418A1 (en) | Methods of treating autism spectrum disorder using aminosterol compositions | |
US20240115550A1 (en) | Treatment of mental disorders | |
WO2024160389A1 (en) | 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers | |
WO2024160391A1 (en) | Treatment of mental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514057 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004773271 Country of ref document: EP Ref document number: 2007054940 Country of ref document: US Ref document number: 10572090 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004773271 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10572090 Country of ref document: US |